Summary Previous studies have shown that sera from patients with pancreatic cancer often contain a mucus glycoprotein that expresses the oncofetal antigen galactose 1-3, N-acetyl galactosamine, which is the T blood group antigen and the binding site for the lectin peanut agglutinin (PNA). An enzyme-linked lectin assay has been developed to quantify PNA-binding glycoproteins in serum and has been evaluated as a serological test for pancreatic cancer. Sera were studied from 53 patients with pancreatic cancer and 154 controls, including benign obstructive jaundice, acute and chronic pancreatitis, chronic liver disease and inflammatory bowel disease. The enzyme-linked peanut lectin assay proved highly reproducible and has 77% sensitivity and 83% specificity for pancreatic cancer, results that are very similar to those achieved in the same sera by CA19-9 radioimmunoassay (75% sensitivity, 82% specificity with the upper limit of normal set at 37uml-1). CEA assay pro.ved less useful (60% sensitivity, 47% specificity). In this study better results were obtained if an upper limit of normal of 50uml-1 was used for CAl9-9 (75% sensitivity, 92% specificity). Combination of CA19-9 assay with the upper limit set at 50uml-i and the peanut lectin assay improved the sensitivity to 85% with only a slight fall in specificity (85%). These results compare well with published results for ultrasound and CT scanning.
Pancreatic cancer can be notoriously difficult to diagnose, particularly in the non-jaundiced patient, and there is a need for better and simpler diagnostic tests which might allow the diagnosis to be made or excluded without recourse to more invasive tests. Symptomatic pancreatic cancer is sadly almost always incurable and if a high degree of diagnostic accuracy could be achieved a simple test that could be used for screening pre-symptomatic patients could be very valuable if some way could be found of defining a high risk population.
Several tumour associated antigens have been described in pancreatic cancer sera. These include carcinoembryonic antigen (CEA) (Gold & Freedman, 1965; Tatsuta et al., 1984) , pancreatic oncofetal antigen (POA) (Banwo et al., 1974; Nishida et al., 1985) , pancreatic cancer associated antigen (PCAA) (Chu et al., 1977; Loor et al., 1984) , (Metzgar et al., 1984; Sawaku et al., 1986) , CA19-9 (Koprowski et al., 1979; Haglund et al., 1986b) , CA50 (Lindholm et al., 1983; Habib et al., 1986) and CA12-5 (Lehmann et al., 1984; Haglund, 1986) . The most successful of these has proved to be CA19-9, which recognises the sialylated blood group Lewis antigen, which is expressed on a mucin secreted by the pancreatic tumour into the serum (Magnani et al., 1983) . However, most published studies have shown a considerable overlap between CA19-9 serum levels in pancreatic cancer and controls (Haglund et al., 1986; Savarino et al., 1984; Tatsuta et al., 1985; Harmenberg et al., 1988) . It contain the high molecular weight abnormal glycoprotein was performed and 100,lp of these diluted samples applied in duplicate to coat micro-ELISA plates for 16h at 4°C. The plates were then washed and quenched in PBS/Tween 20 (0.1%) buffer for 1 h at room temperature followed by incubation with three different concentrations of peroxidasetagged PNA lectin (12.5Sgrmn-1, 6.25pgml-1 and 3.125pgml-1) for each set of the serially diluted samples. Unbound lectins were removed by washing with PBS/Tween 20 buffer three times after 16h incubation at 4°C. Peroxidase activity was detected by a combination of 0-phenylenediamine (10 mg) and H202 (40 pl) in phosphate citrate buffer (25 ml, pH 5.0). Reaction was allowed to proceed for 10min at room temperature and then terminated by addition of 4M H2SO4. Optical density was read at 492 nm using a standard micro-ELISA reader (CLS, 962 microplate reader, Cambridge, UK).
Results obtained using 12.5 pgml 1 peroxidase-PNA were shown to be optimal (Figure 1 ). At this concentration, 1:20,000 dilution of the positive control serum gave on o.d. of 1.0. Subsequent experiments were carried out using 1:20,000 dilution of sera and 12.5 pgml 1 peroxidase-PNA.
Determination of total serum peanut lectin binding activity (PLBA) Duplicates of Ip00ul (1: 20,000) diluted serum samples and serially diluted positive control sera were incubated on the ELISA plate for 16 h at 4°C. Pancreatic cancer and control sera were randomly distributed on the ELISA plate and assayed blind. The plate was washed x 3 and quenched with PBS/Tween 20 buffer and then l00p1 peroxidase-PNA (12.5 pgml-1) was applied in each well and incubated at 4°C for 16 h. Unbound peroxidase-PNA was then washed off using the same buffer and bound lectin identified using 0-phenylenediamine and H202 in phosphate citrate buffer as described before. The o.d. of test sera was measured and converted into units PLBA per ml with reference to the positive control serum. The same positive control serum from a patient with histologically proven pancreatic cancer was used throughout all the assays. 1 unit PLBA ml-1 was arbitrarily defined as peanut agglutinin binding activity equivalent to a 1:20,000 dilution of this positive control serum. The upper limit of the normal range was taken as the value (0.6uml-1) which included 95% of the normal sera. Intraplate and interplate variation was assessed with the help of four additional internal standards (two normal and two pancreatic cancer sera).
RIA CA 19-9 and RIA CEA Radioimmunoassays for CA19-9 and CEA were performed according to the manufacturers' instructions (CIS, UK). Standards and sera undergoing test were incubated in polystyrene tubes pre-coated with CAI9-9 or CEA antibodies. Unbound antigens were removed by repeated ( x 3) washings with either distilled water or Tween 20 buffer followed by incubation with 1251 labelled anti-CA19-9 or 1251 anti-CEA antibodies. Unbound antibodies were removed by further washings and radioactivity determined using a gamma counter (minigamma, Pharmacia-LKB, Sweden).
Statistical analysis
Statistical analysis of marker activity in advanced versus localised disease was performed using Wilcoxon's rank sum test.
Results
Enzyme-linked lectin assay (PNA-ELLA) The intraplate and interplate variation were found to be 8.1% and 7.5% respectively, indicating good reproducibility (Table I) . When 0.6 u PLBA ml-1 is taken as the normal cutoff limit, this assay has a sensitivity of 77% and specificity of 83% for pancreatic cancer (malignant controls were excluded from the latter calculation) (Figure 2 ). The positive predictive value is 68% and negative predictive value 89%.
There was no apparent difference in levels of PLBA between the jaundiced and non-jaundiced patients with pancreatic
cancer. However, patients with metastatic disease (T1 _ 3, N1I2, M1) have significantly higher PLBA than those with localised disease (T1 I, N,o MO) (P<0.02) (Figure 3 ).
CA 19-9 RIA This assay had a sensitivity of 75% and specificity of 82% for pancreatic cancer (malignant controls excluded) when the normal cut-off limit was set according to the manufacturer's recommendation at 37 u ml-1 (Figure 4 ). The positive predictive and negative predictive values are 67 and 88% respectively. These results are very similar to PNA-ELLA. Patients with extensive disease similarly had significantly higher CA19-9 levels than those with localised disease (P<0.05) (Figure 3) . If the normal cut-off limit for CAl9-9 was raised to 50 u ml-1 the specificity improved to 92% without any reduction in sensitivity in this study.
CEA RIA CEA RIA had the poorest sensitivity (60%) and specificity (47%) for pancreatic cancer among the three assays tested with the normal cut-off limit set at 2.5ngml-1 ( Figure 5 ). Normal CEA levels were found in the majority of the normal healthy controls but many of the non-malignant disease control sera had high CEA levels. The positive predictive and negative predictive values were also inferior to PNA-ELLA and CA19-9 RIA. However, CEA levels did correlate with stage of disease (P<0.05) (Figure 3 ).
Combination of PNA-ELLA and Ca19.9
In this study we were unable to achieve better sensitivity for pancreatic cancer by adjustment of normal cut-off limits in any of these three assays without severely reducing specificity. However, combination of PNA-ELLA and CA19-9 RIA, with upper limits of normal set at 0.85uml-1 (PNA-ELLA) and 50uml-1 (CA19-9) improved the sensitivity to 85% with a specificity of 85%. The addition of CEA to these two assays only marginally increased the sensitivity (87%) but at the expense of a considerable drop in specificity (68%) ( ..
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This study shows that an enzyme-linked peanut lectin binding assay can be used to detect tumour-related glycoproteins present in the serum of patients with pancreatic cancer. It is reproducible and easy to perform and has a sensitivity (77%) and specificity (82%) comparable to that for CA19-9 radioimmunoassay. Most of the serological tumour associated antigens so far described have been discovered by developing monoclonal antibodies against tumour extracts but it has become apparent that most of these markers are heavily glycosylated glycoproteins and in many cases the epitope for the monoclonal antibody has proved to be a complex carbohydrate rather than a protein. Lectins are plant or animal glycoproteins with specificity for carbohydrates and are proving useful tools in the detection of glycoprotein alterations in malignant disease. Peanut agglutinin (PNA), which binds to the exposed Thomson Friedenreich antigen (galactose 1-3, N-acetyl galactosamine) on desialylated cell surface and mucus glycoproteins, has probably been the most widely used. It has been shown to bind to neoplastic colonic (Boland et al., 1982) , gastric (Martin & Wilbur, 1985) , breast (Howard et al., 1981) and lymphoid (Veerman et al., 1985) tissue with little or no binding to normal tissues from these sites. It does, however, also bind to hyperplastic or adenomatous colonic mucosa (Rhodes et al., 1986) so is not totally specific for epithelial malignancy.
Lectin histochemistry of the pancreas has shown some cytoplasmic PNA positivity even in normal tissue but in pancreatic cancer strong PNA positive mucin is often seen . CA19-9 positivity is also found in normal pancreas (Haglund et al., 1986a) and it seems likely from lectin and immunoblotting studies ) that the high levels of PNA and CA19-9 binding activity in pancreatic cancer sera reflect mucin, which is probably structurally immature, i.e. incompletely glycosylated and sialylated, and which has been shed into the serum. It is interesting that sera from colorectal cancer patients less frequently contain this mucin despite the facts that CA19-9 was originally developed against a colorectal cancer cell line and that colorectal cancers are usually PNA positive. It seems likely that pancreatic cancers either secrete more mucin than colorectal cancers or invade blood vessels more readily. Positive results with either PNA-ELLA or CA19-9 assay clearly have to be expected in some patients with epithelial cancers other than pancreatic cancer but providing the clinician is aware of this it should not prove a great problem.
Radioimmunoassay with CA19-9 has up till now been the most successful serological test for pancreatic cancer but its main disadvantage apart from cost has been a fairly high false positive rate in patients with benign obstructive jaundice, benign liver disease or benign pancreatic disease (Haglund et al., 1986b; Piantino et al., 1986; Satake et al., 1985) , including cystic fibrosis (Roberts et al., 1986) in which it is elevated in 87% of cases. This reflects the fact that the CA19-9 epitope is present in normal bile (Albert et al., 1987) and pancreatic juice (Schmiegel et al., 1985) . PNA-ELLA shows very similar overall sensitivity and specificity to CA19-9 assay. However, there is a basic difference in their epitope structures. PNA identifies the disaccharide galactose 1-3, N-acetyl galactosamine which is usually present as the base carbohydrate pair on desialylated mucin side chains whereas CA19-9 antibody recognises a complex carbohydrate structure, sialylated N-fucopentaose II oligosaccharide. Thus the mucin carbohydrate side chain identified by PNA lectin is shorter and likely to be more immature than the side chain identified by CA19-9 antibody, which is more heavily glycosylated and sialylated.
There is an increasing tendency for tumour marker assays to be performed using a combination of two or three markers. This approach seems particularly logical in pancreatic cancer where the tumour has been shown to secrete a very large mucus glycoprotein which potentially bears a large number and variety of carbohydrate epitopes. For example the combination of CA19-9 and DU-PAN-2 assay has recently been shown to be more sensitive than either assay alone (Takasaki et al., 1988) . This study has shown that the combination of PNA-ELLA and CA19-9 radioimmunoassay has a sensitivity of 85%, specificity of 85% and positive predictive value of 68%, results which compare very well with other more elaborate tests such as ultrasonography or computerised tomography. This level of specificity is, however, still not sufficiently high for screening an asymptomatic population for a relatively uncommon condition (even a 1% false positive rate would result in 1,000 healthy patients undergoing further investigation for every nine patients with pancreatic cancer, assuming an incidence of 9 per 100,000).
The enzyme linked peanut lectin assay is cheap, easy to perform and reproducible and its use, probably in combination with CA19-9 radioimmunoassay should prove helpful in the diagnosis of pancreatic cancer. C.K.C. is an Amelie Waring research fellow of the British Digestive Foundation.
